Clinical Trial

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability, and pharmacokinetics following multiple ascending oral doses in healthy adult participants (Part 2).
Protocol Amendment History 1 change
critical Trial completed 2026-06-05
Trial Details
NCT Number NCT07566130
Lead Sponsor AbbVie
Conditions Healthy Volunteers
Enrollment 93 participants
Start Date 2025-04-18
Primary Completion 2026-05-07 (estimated)
Study Completion 2026-05-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-04